Multimodal Treatment of Primary Advanced Ovarian Cancer

Epithelial ovarian cancer is the second most common malignancy of female genital tract, with approximately 7,400 new cases annually in Germany. With 5,500 deaths per year, leading gynecologic cause death. characterized by morphologic heterogeneity 4 molecular biological subtypes (immunoreactive-like, differentiated-like, proliferative-like, mesenchymal-like) different prognosis. Significantly improved survival achieved optimal debulking no residual disease (R0). Systematic lymphonodectomy clinical negative lymph nodes has effect on overall advanced cancer. Interval after three cycles neoadjuvant chemotherapy carboplatin/paclitaxel controversial. Standard for consists six carboplatin AUC5 and paclitaxel 175 mg/m2, a three-week cycle. Intraperitoneal not standard therapy. Anti-hormonal therapy an aromatase inhibitor plays minor role both low grade serous (LGSOC) high (HGSOC). A major achievement been results SOLO-1 trial, which olaparib as first line maintenance monotherapy resulted 70% lower risk progression patients Breast Cancer Gene (BRCA)-mutated